1.9200 -0.07 (-3.52%)
After hours: 7:22PM EDT
|Bid||1.9200 x 3000|
|Ask||1.9600 x 4000|
|Day's Range||1.8000 - 1.9900|
|52 Week Range||1.3800 - 9.2600|
|Beta (5Y Monthly)||1.82|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 05, 2020 - May 10, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||7.13|
BioCryst Pharmaceuticals, Inc. (BCRX) today announced the appointment of Anthony Doyle as senior vice president and chief financial officer (CFO). Mr. Doyle joins BioCryst from Worldwide Clinical Trials, a full-service global contract research organization, where he has served as CFO since 2014. From 2004 to 2012, Mr. Doyle held a series of increasingly responsible roles at General Electric (GE), moving through FP&A, controller, audit, tax and commercial finance rotations in the GE Financial Management and Corporate Audit Staff finance and leadership training programs.
After the Dow sees a quarter as ugly as this year's first quarter, the 124-year old index on average returns 11.8% in the following quarter. There is similar positive trend for the S&P 500 as well.
BioCryst Pharmaceuticals, Inc. (BCRX) announced that the European Medicines Agency (EMA) has validated its marketing authorization application (MAA) submission for approval of oral, once-daily berotralstat (BCX7353) for the prevention of hereditary angioedema (HAE) attacks. With this validation, the EMA has begun their formal review of the MAA under the centralized procedure for all member states of the European Union, and Norway, Iceland and Liechtenstein. “Berotralstat would represent the first targeted oral therapy approved for HAE prophylaxis in Europe and would deliver a major advance in therapy to HAE patients,” said Jon Stonehouse, chief executive officer of BioCryst.
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
BioCryst Pharmaceuticals, Inc. (BCRX) today announced new data from the APeX-2 trial showing 150 mg of oral, once-daily berotralstat (BCX7353) for prophylaxis of hereditary angioedema (HAE) attacks reduced patients’ monthly use of standard of care (SoC) on-demand medicine by 53.6 percent (p
There's a growing consensus that the Triangle is not only strapped for the venture capital needed to make innovative ideas coming out of local universities work, but it is also severely lacking in the kind of corporate leadership needed to guide innovation to successful commercial companies.
BioCryst (BCRX) has been upgraded to a Zacks Rank 1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
STOCKSTOWATCHTODAY BLOG Investors are staring at a sea of red Monday morning as Covid-19 coronavirus fears escalate and as oil-producing countries battle over output levels. Hong Kong’s Hang Seng Index fell 4.
BioCryst (BCRX) delivered earnings and revenue surprises of 92.00% and 230.49%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
—Berotralstat NDA accepted by FDA; PDUFA date December 3, 2020— —JNDA accepted by PMDA under Sakigake timeline; approval expected 2H 2020— —PNH proof of concept data with oral.
BioCryst Pharmaceuticals, Inc. (BCRX) today announced the first patients have been dosed with BCX9930 in a proof of concept trial in paroxysmal nocturnal hemoglobinuria (PNH). BCX9930 is an oral Factor D inhibitor discovered and developed by BioCryst for the treatment of complement-mediated diseases. The company expects to report data from the proof of concept study in PNH patients in the second quarter of 2020.
RESEARCH TRIANGLE PARK, N.C., March 03, 2020 -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company will present at the Barclays Global Healthcare.
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted 10 newly-hired employees options to purchase an aggregate of 333,000 shares of BioCryst common stock on February 28, 2020 as inducements material to each employee entering into employment with BioCryst. The options were granted in accordance with NASDAQ Listing Rule 5635(c)(4). The options have an exercise price of $3.00 per share, which is equal to the closing price of BioCryst common stock on the last business day prior to the grant date.
BioCryst (BCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
RESEARCH TRIANGLE PARK, N.C., Feb. 27, 2020 -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company will present abstracts with new data on.
Airlines, hotels, casinos and other stocks continue to fall as fear of the coronavirus grows worldwide and all but halts activity in the virus epicenter of Wuhan, China. Alpha Pro Tech, Ltd. (NYSE: APT) manufactures masks and protective apparel — goods already in high demand in China. Lakeland Industries, Inc. (NASDAQ: LAKE) also produces protective clothes for high-risk workers, such as the medical professionals and public health officials exposing themselves to patients.
BioCryst Pharmaceuticals, Inc. (BCRX) today announced that the company has appointed former Pfizer chief financial officer (CFO), Alan G. Levin, to its board of directors (BOD). In addition to his 20-year career at Pfizer, Mr. Levin served as CFO of Endo Pharmaceuticals, Inc. over a five-year period where the company experienced a nearly 400 percent increase in its market capitalization. From 2014 through 2019, Mr. Levin served on the BOD of Aceto Corporation, a multinational company involved in the sale and distribution of generic drugs, pharmaceutical intermediates and performance chemicals.
RESEARCH TRIANGLE PARK, N.C., Feb. 20, 2020 -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its fourth quarter and full year 2019.
BioCryst Pharmaceuticals, Inc. (BCRX) announced that the U.S. Food and Drug Administration (FDA) has accepted and filed its new drug application (NDA) for the approval of oral, once daily berotralstat (BCX7353) for the prevention of hereditary angioedema (HAE) attacks. The Prescription Drug User Fee Act (PDUFA) date for the NDA is December 3, 2020. In the NDA filing acceptance letter, the FDA stated that they are not currently planning to hold an advisory committee meeting to discuss the NDA.